Trial of Antimycobacterial Therapy in Sarcoidosis

Phase 1/2 Completed 30 enrolled Vanderbilt University

RandomizedParallel-groupSingle-blindDiagnostic

Summary

Growing research from independent laboratories provide an association between mycobacteria and sarcoidosis. More recent immunologic and molecular studies demonstrate immune responses to mycobacteria virulence factors. The purpose of this study is to assess if administration of anti-mycobacterial drug therapy will aid in resolution of cutaneous sarcoidosis lesions.

Timeline

Start: 2010-02
Primary completion: 2011-02
Completion: 2011-02

Publications

Drake WP, Oswald-Richter K, Richmond BW, Isom J, Burke VE, Algood H, Braun N, Taylor T, Pandit KV, Aboud C, Yu C, Kaminski N, Boyd AS, King LE. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatol. 2013 Sep;149(9):1040-9. doi: 10.1001/jamadermatol.2013.4646.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Azithromycin	Small molecule	250 mg	Oral
Subject	Ethambutol	Small molecule	15 mg/kg	Oral
Subject	Ethambutol	Small molecule	25 mg/kg	Oral
Subject	Levofloxacin	Small molecule	500 mg	Oral
Subject	Rifampin	Small molecule	5 mg/kg	Oral
Subject	Rifampin	Small molecule	10 mg/kg	Oral

Trial of Antimycobacterial Therapy in Sarcoidosis

Summary

Timeline

Publications

Drugs

Indications